Results 341 to 350 of about 349,757 (388)
Some of the next articles are maybe not open access.
Antibody-Drug Conjugate Targets, Drugs and Linkers.
Current Cancer Drug Targets, 2022Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a malignant tumor while sparing normal tissue. The challenge is to select an antibody target expressed exclusively or at highly elevated levels on the surface of ...
B. Teicher, Joel Morris
semanticscholar +1 more source
What makes a good antibody–drug conjugate?
Expert Opinion on Biological Therapy, 2021Introduction: Antibody-Drug Conjugates (ADCs) are becoming increasingly important weapons in the fight against cancer, as evidenced by the growing number of approved products.
Martin De Cecco +2 more
semanticscholar +1 more source
Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy.
Journal of Medicinal Chemistry, 2021Antibody-drug conjugate (ADC) and immune checkpoint blockade (ICB) offer promising approaches for cancer treatment. Here, we describe an ADC constructed by conjugating anti-PD-L1 THIOMAB with a bifunctional immunomodulator D18 via a redox-cleavable ...
Lei He +9 more
semanticscholar +1 more source
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Expert Opinion on Biological Therapy, 2020Introduction We describe a new, third-generation of antibody-drug conjugates (ADCs) having a high drug payload against topoisomerase I, important for DNA function, and targeting selective tumor antigens, predominantly TROP-2. Areas Covered The historical
D. Goldenberg, R. Sharkey
semanticscholar +1 more source
Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
openaire +3 more sources
Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +2 more sources
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
openaire +2 more sources
Toxicities From Antibody-Drug Conjugates
The Cancer Journal, 2022Abstract Antibody-drug conjugates are becoming increasingly important in the treatment of many cancer types. The 3 main structural components—antibody, linker, and payload—each contribute to the toxicity profiles of these drugs. In addition to cytopenias and gastrointestinal adverse effects attributed to the chemotherapy payloads, each drug ...
Andrew C, Johns, Matthew T, Campbell
openaire +2 more sources
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl +3 more
openaire +2 more sources
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Journal of the National Cancer Institute, 2019Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.
M. Birrer +3 more
semanticscholar +1 more source
Antibody–Drug Conjugates in Uro-Oncology
Targeted Oncology, 2022Currently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment.
Dawid Sigorski +3 more
openaire +2 more sources